1-4 of 4
Paul Giangrande
Close
Sort by
Journal Articles

Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),

Flora Peyvandi, MD, PhD, Roberta Palla, Marzia Menegatti, Simona M Siboni, Susan Halimeh, Britta Faeser, Helen Pergantou, Heleni Platokouki, Paul Giangrande, Kathelijne Peerlink, Tiraje Celkan, Nihal Ozdemir, Christoph Bidlingmaier, Jorgen Ingerslev, Muriel Giansily-Blaizot, Jean-Francois Schved, Ruth Gilmore, Alain P. Gadisseur, Majda Benedik-Dolnicar, Lidija Kitanovski, Danijela Mikovic, Khaled M Musallam, Frits R. Rosendaal, PhD
Journal: Blood
Blood (2011) 118 (21): 3312.
https://doi.org/10.1182/blood.V118.21.3312.3312
Published: 2011
Journal Articles

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

Clinical Trials & Observations
Claude Negrier, Karin Knobe, Andreas Tiede, Paul Giangrande, Judi Møss
Journal: Blood
Blood (2011) 118 (10): 2695–2701.
https://doi.org/10.1182/blood-2011-02-335596
Published: 2011
Journal Articles

Detection of F8 Mutations by High Resolution Melting (HRM) Analysis.

Patricia A Bignell, David M. Keeling, MD, Paul Giangrande, MD
Journal: Blood
Blood (2008) 112 (11): 1226.
https://doi.org/10.1182/blood.V112.11.1226.1226
Published: 2008
Journal Articles

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Jay M. Feingold, MD, PhD, Mark P. Smith, MD, Richard Littlewood, MD, Paul Giangrande, MD, ReFacto STL Study Group
Journal: Blood
Blood (2004) 104 (11): 4023.
https://doi.org/10.1182/blood.V104.11.4023.4023
Published: 2004